Board Meeting Details

The Board of Directors meeting was held on Monday, August 10, 2026, commencing at 05:30 p.m. and concluding at 07:05 p.m.

Documents Approved

The Board approved:

  • Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026
  • Limited Review Report on the unaudited Financial Results (Standalone and Consolidated) for the said quarter

Standalone Financial Results (₹ in million)

Quarter Ended June 30, 2026 (Unaudited) vs Comparative Periods:

Continuing Operations:

  • Revenue from operations: ₹671 million (Q1 FY26: ₹595 million; Q4 FY26: ₹703 million)
  • Other income: ₹1 million (Q1 FY26: ₹7 million; Q4 FY26: ₹5 million)
  • Total income: ₹672 million (Q1 FY26: ₹602 million; Q4 FY26: ₹708 million)
  • Total expenses: ₹574 million (Q1 FY26: ₹537 million; Q4 FY26: ₹580 million)
  • Employee benefits expense: ₹283 million (Q1 FY26: ₹232 million; Q4 FY26: ₹248 million)
  • Finance costs: ₹9 million (Q1 FY26: ₹30 million; Q4 FY26: ₹9 million)
  • Depreciation and amortization expense: ₹14 million (Q1 FY26: ₹15 million; Q4 FY26: ₹13 million)
  • Profit before exceptional items and tax: ₹98 million (Q1 FY26: ₹65 million; Q4 FY26: ₹128 million)
  • Exceptional items: Nil (Q4 FY26: ₹87 million)
  • Profit before tax: ₹98 million (Q1 FY26: ₹65 million; Q4 FY26: ₹41 million)
  • Tax expense: ₹25 million (Current: ₹20 million; Deferred: ₹5 million) (Q1 FY26: ₹24 million; Q4 FY26: ₹-531 million)
  • Profit for the period from continuing operations: ₹73 million (Q1 FY26: ₹41 million; Q4 FY26: ₹572 million)

Discontinued Operations:

  • Profit after tax from discontinued operations: Nil (Q1 FY26: ₹17 million)

Total Performance:

  • Profit for the period: ₹73 million (Q1 FY26: ₹58 million; Q4 FY26: ₹572 million)
  • Other comprehensive income: ₹1 million (Q1 FY26: ₹-1 million; Q4 FY26: ₹-1 million)
  • Total comprehensive income: ₹74 million (Q1 FY26: ₹57 million; Q4 FY26: ₹571 million)

Earnings Per Share (₹):

  • Basic EPS (continuing operations): 0.46 (Q1 FY26: 0.26; Q4 FY26: 3.59)
  • Diluted EPS (continuing operations): 0.46 (Q1 FY26: 0.26; Q4 FY26: 3.59)
  • Basic EPS (total): 0.46 (Q1 FY26: 0.36; Q4 FY26: 3.59)
  • Diluted EPS (total): 0.46 (Q1 FY26: 0.36; Q4 FY26: 3.59)

Capital Structure:

  • Paid-up equity share capital: ₹159 million (unchanged from previous periods)
  • Reserves excluding revaluation reserves: ₹22,964 million (as of March 31, 2026)

Consolidated Financial Results (₹ in million)

Quarter Ended June 30, 2026 (Unaudited) vs Comparative Periods:

  • Revenue from operations: ₹22,294 million (Q1 FY26: ₹19,007 million; Q4 FY26: ₹22,900 million)
  • Sales/Income from operations: ₹22,211 million
  • Other operating income: ₹83 million
  • Other income: ₹199 million (Q1 FY26: ₹120 million; Q4 FY26: ₹237 million)
  • Total income: ₹22,493 million (Q1 FY26: ₹19,127 million; Q4 FY26: ₹23,137 million)
  • Total expenses: ₹21,629 million (Q1 FY26: ₹17,582 million; Q4 FY26: ₹21,240 million)
  • Cost of materials consumed: ₹6,383 million
  • Purchases of stock-in-trade: ₹869 million
  • Changes in inventories: ₹235 million
  • Employee benefits expense: ₹7,535 million
  • Finance costs: ₹542 million
  • Depreciation, amortization and impairment expense: ₹1,273 million
  • Other expenses: ₹4,792 million
  • Profit before share of loss of associate and exceptional items: ₹864 million (Q1 FY26: ₹1,545 million; Q4 FY26: ₹1,897 million)
  • Share of loss of an associate: Nil (Q1 FY26: ₹-1 million)
  • Profit before exceptional items and tax: ₹864 million (Q1 FY26: ₹1,544 million; Q4 FY26: ₹1,897 million)
  • Exceptional items: Nil (Q4 FY26: ₹137 million)
  • Profit before tax: ₹864 million (Q1 FY26: ₹1,544 million; Q4 FY26: ₹1,760 million)
  • Tax expense: ₹300 million (Current: ₹296 million; Deferred: ₹4 million) (Q1 FY26: ₹519 million; Q4 FY26: ₹567 million)
  • Profit for the period: ₹564 million (Q1 FY26: ₹1,025 million; Q4 FY26: ₹1,193 million)
  • Other comprehensive loss: ₹-191 million (Q1 FY26: ₹411 million; Q4 FY26: ₹2,819 million)
  • Total comprehensive income: ₹373 million (Q1 FY26: ₹1,436 million; Q4 FY26: ₹4,012 million)

Attribution of Results:

  • Profit attributable to owners of the Company: ₹565 million (Q1 FY26: ₹1,029 million; Q4 FY26: ₹1,194 million)
  • Profit attributable to non-controlling interest: ₹-1 million (Q1 FY26: ₹-4 million; Q4 FY26: ₹-1 million)

Earnings Per Share (₹):

  • Basic EPS: 3.57 (Q1 FY26: 6.49; Q4 FY26: 7.55)
  • Diluted EPS: 3.56 (Q1 FY26: 6.47; Q4 FY26: 7.52)

Capital Structure:

  • Paid-up equity share capital: ₹158 million (unchanged from previous periods)
  • Reserves excluding revaluation reserves: ₹70,770 million (as of March 31, 2026)

Segment-wise Performance (Consolidated)

Revenue by Segment (₹ in million):

  • Radiopharma: ₹10,221 million
  • Allergy Immunotherapy: ₹2,144 million
  • Contract Development and Manufacturing Organisation - Sterile Injectables: ₹5,198 million
  • Contract Research, Development and Manufacturing Organisation: ₹3,258 million
  • Generics: ₹1,734 million
  • Proprietary Novel Drugs: Not specified
  • Total segment revenue: ₹22,152 million
  • Unallocable corporate: ₹142 million

Segment Results (Profit/Loss before tax, exceptional items and interest):

  • Radiopharma: ₹780 million profit
  • Allergy Immunotherapy: ₹635 million profit
  • Contract Development and Manufacturing Organisation - Sterile Injectables: ₹73 million profit
  • Contract Research, Development and Manufacturing Organisation: ₹356 million profit
  • Generics: ₹-101 million loss
  • Proprietary Novel Drugs: ₹-76 million loss

Subsidiaries and Associates

The consolidated results include 39 subsidiaries and 1 associate (SPV Laboratories Private Limited).

Auditor Review

The financial results were subjected to limited review by Walker Chandiok & Co LLP, Chartered Accountants, who issued an unmodified review conclusion.

Additional Information

The documents will be posted on the company's website at www.jubilantpharmova.com.